Yamada S, Yamamura H I, Roeske W R
Life Sci. 1982 Sep 13;31(11):1161-70. doi: 10.1016/0024-3205(82)90091-1.
The beta-adrenergic and muscarinic cholinergic receptors in the splenic homogenates of control and 6-hydroxydopamine (6-OHDA) treated rats were characterized. The specific binding of [3H]dihydroalprenolol (DHA) and [3H]quinuclidinyl benzilate (QNB) in the rat spleen were saturable and of high affinity and showed pharmacological specificity of splenic beta-adrenergic and muscarinic cholinergic receptors. Following 6-OHDA treatment, the Bmax value for specific 3HDHA binding to the rat spleen was significantly increased by 26 percent and 22 percent compared to control at 2 and 3 weeks without a change in the Kd. In contrast, there was a 38 percent decrease in the Bmax for 3HQNB in the 6-Ohda treated rat spleen at 2 and 3 weeks respectively without a change in the Kd. The Bmax value at 5 weeks was significantly greater than that at 2 or 3 weeks. The splenic norepinephrine (NE) concentration was markedly reduced by the 6-OHDA treatment at 1 to 3 weeks, while there was a significant recovery in the splenic NE concentration at 5 weeks. Thus, our results strongly suggest that we are biochemically localizing muscarinic cholinergic receptors on the sympathetic nerves of the rat spleen and that the beta-adrenergic receptors of the spleen are localized postsynaptically.
对对照组和6-羟基多巴胺(6-OHDA)处理的大鼠脾脏匀浆中的β-肾上腺素能受体和毒蕈碱型胆碱能受体进行了表征。大鼠脾脏中[3H]二氢阿普洛尔(DHA)和[3H]喹核醇基苯甲酸酯(QNB)的特异性结合具有饱和性和高亲和力,显示出脾脏β-肾上腺素能受体和毒蕈碱型胆碱能受体的药理学特异性。6-OHDA处理后,与对照组相比,在第2周和第3周时,大鼠脾脏中特异性3HDHA结合的Bmax值分别显著增加了26%和22%,而Kd无变化。相比之下,在6-OHDA处理的大鼠脾脏中,第2周和第3周时3HQNB的Bmax分别下降了38%,而Kd无变化。第5周的Bmax值显著高于第2周或第3周。6-OHDA处理在1至3周时使脾脏去甲肾上腺素(NE)浓度显著降低,而在第5周时脾脏NE浓度有显著恢复。因此,我们的结果强烈表明,我们在生化水平上定位了大鼠脾脏交感神经上的毒蕈碱型胆碱能受体,并且脾脏的β-肾上腺素能受体位于突触后。